Screening of Latent Tuberculous Infection (LTBI) before Starting Anti-Tumor Necrosis Factor Therapy in Patients with Psoriasis
Swetalina Pradhan, Bhushan Madke, Shekhar Neema, Poonam Kabra, Adarsh Lata Singh, Sangita Yadav
Indian Journal of Dermatology · 2021-09
Abstract
Anti-tumor necrosis agents are being increasingly used in the management of moderate to severe psoriasis. Therapy with antitumor necrosis factor alpha (TNF-α) agents is being fraught with reactivation of latent tuberculosis infection (LTBI). This paper addresses the intricate relation between LTBI and anti-TNF-α agents and provides working guidelines for screening of LTBI and its management before prescribing anti-TNF-α therapy in patients with psoriasis.
MeSH terms
- Medicine
- Latent tuberculosis
- Psoriasis
- Tuberculosis
- Necrosis
- Tumor necrosis factor alpha
- Immunology
- Mycobacterium tuberculosis
- Tumor necrosis factor α
- Internal medicine
- Combination therapy
- Isoniazid